Sio Capital Management’s Aptose Biosciences, Inc. APTO Stock Holding History

Sio Capital Management’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-91	Closed	-$246K	–	100
2021 Q1	$246K	Buy	+91	New	+$180K	0.05%	87
2020 Q1	–	Sell	-111	Closed	-$284K	–	95
2019 Q4	$284K	Buy	+111	New	+$145K	0.07%	68

Other funds holding APTO

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

P.A.W. Capital Greenwich, Connecticut $36.7M AUM 6.81% 1-Year Est. Return

Sio Capital Management's APTO Position: Q2 2021 in Review

Sio Capital Management sold out of Aptose Biosciences, Inc. (APTO) in Q2 2021, closing a stake of 91 shares — an estimated $246K sold.

Sio Capital Management first reported a position in APTO in Q4 2019 and held it in 2 quarters. The position peaked at $284K in Q4 2019. 63 funds tracked by Wall St. Rank hold APTO as of Q2 2021.

Sio Capital Management reported no remaining Aptose Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
Sio Capital Management sold 91 Aptose Biosciences, Inc. shares in Q2 2021, an estimated $246K.
Sio Capital Management first reported a position in Aptose Biosciences, Inc. in Q4 2019 and held it in 2 quarters.
Sio Capital Management's Aptose Biosciences, Inc. position peaked at $284K in Q4 2019.
63 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2021.

Based on Sio Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.